These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9855525)

  • 1. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
    Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
    J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
    Prince HE; Lapé-Nixon M; Audette C; Van Horn K
    J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F; Schellekens H; Bertolotto A
    J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
    Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
    Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.
    Vartanian TK; Zamvil SS; Fox E; Sorensen PS
    Neurology; 2004 Dec; 63(11 Suppl 5):S42-9. PubMed ID: 15596736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
    Gilli F; De La Torre AL; Royce DB; Pachner AR
    Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of interferon beta: differences among products.
    Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
    Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD; Quinless JR; Jotkowitz A; Beaton P;
    Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.